<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25850">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770235</url>
  </required_header>
  <id_info>
    <org_study_id>PI2013_843_0021</org_study_id>
    <nct_id>NCT02770235</nct_id>
  </id_info>
  <brief_title>Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients</brief_title>
  <acronym>APGADEPD</acronym>
  <official_title>Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In diabetics there is an abnormally increased production of AGEs due to hyperglycemia. An
      association was shown between AGE measured by biopsy (invasive) and DE patients with
      diabetes (increase of AGE level in the corpora cavernosa). To date no studies have explored
      the link between DE and the measure of AGE by a non-invasive method of Auto-fluorescence
      (AF) Skin (AGEReaderTM).

      If the hypothesis of an association between DE and AGE measured by AF was checked, screening
      for erectile dysfunction and measurement of AGEs could help to improve the overall
      management of diabetic patient (including cardiovascular) and their quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>erectile dysfunction and AGE levels</measure>
    <time_frame>2 hours</time_frame>
    <description>To evaluate the association between erectile dysfunction and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>DE assessment and AGE measurements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DE assessment</intervention_name>
    <description>by a validated self-administered questionnaire: Index International erectile function (IIEF-15)</description>
    <arm_group_label>DE assessment and AGE measurements</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AGE measurement</intervention_name>
    <description>By AGE-ReaderTM</description>
    <arm_group_label>DE assessment and AGE measurements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Type 2

        Exclusion Criteria:

          -  skin hyperpigmentation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youssef KOUIDRAT</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youssef KOUIDRAT</last_name>
    <email>youssefpile@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youssef KOUIDRAT</last_name>
      <email>youssefpile@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>May 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
